Clene Nanomedicine
Clinical trials sponsored by Clene Nanomedicine, explained in plain language.
-
ALS patients gain access to experimental gold nanocrystal treatment
Disease control NO_LONGER_AVAILABLEThis program gave up to 300 people with amyotrophic lateral sclerosis (ALS) access to an experimental drug called CNM-Au8. The goal was to provide treatment, not to formally test if it works. Researchers monitored safety by tracking side effects and lab results. Participants had …
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 17, 2026 08:02 UTC
-
ALS drug CNM-Au8 moves to Open-Label phase: hope for slowing disease?
Disease control OngoingThis study is an optional extension for people with early amyotrophic lateral sclerosis (ALS) who completed a previous placebo-controlled trial. It aims to see if the experimental drug CNM-Au8 is safe and can slow disease progression over a longer period. About 40 participants wi…
Phase: PHASE2 • Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug access for MS patients: hope or hype?
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers up to 25 adults with multiple sclerosis access to an experimental drug called CNM-Au8. The goal is to provide treatment for those who have no other options. It is not a cure, but aims to help control the disease.
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for ALS patients: experimental drug CNM-Au8 now available through expanded access
Disease control TEMPORARILY_NOT_AVAILABLEThis program provides early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Participants must be 18 or older with a confirmed ALS diagnosis and able to take the medication by mouth. The goal is to off…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 11, 2026 20:50 UTC